Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling were re-elected to the Supervisory Board.

At the time of voting 63,8 % of the share capital was represented.

Dr. Michael Majerus, Chairman of the Supervisory Board, stated: "I am particularly pleased that the Annual General Meeting elected Dr. Anna Eichhorn and Mr. Stephen Catling to the Supervisory Board for an additional term. With their outstanding expertise, both are an integral part of the Supervisory Board's work. Majerus continued: "In the past financial year 2023/24, we were able to successfully prepare and conclude two benchmark transactions together with the Executive Board and thus significantly advance the Company's strategic development."

With the publication of the 3M numbers for the financial year 2024/25, the company forecast for the full year a high single-digit to low double-digit percentage increase in sales and an adjusted EBITDA margin of around 10 % in the core segment BRAINBiocatalysts.

In his address to shareholders, CEO Adriaan Moelker said: “Last year was in many respects a year of execution for BRAIN Biotech, as we prepared our path to consistently deliver on our goals. We announced the agreement with Royalty Pharma, which can bring BRAIN Biotech up to 129 million Euro in cash. Shortly thereafter, we announced the licensing agreement with Akribion Therapeutics. Taken together, these two transactions represent tremendous value for our shareholders.”

The detailed voting results and all other documents relating to the Annual General Meeting are available on the website of BRAIN Biotech AG: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2025 .

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Group

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

Biocatalysts Ltd (Production, Distribution)

Website: https://www.biocatalysts.com/

LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn

BRAIN Biotech Zwingenberg (Technologies & R&D Services)

Website: www.brain-biotech.com

LinkedIn: BRAIN Biotech Technologies & Services

AnalyticonDiscovery (R&D)

Web: https://ac-discovery.com/

LinkedIn: https://www.linkedin.com/company/analyticon-discovery/

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.